Neurovive Pharmaceutical Ab

Buck Institute for Research on Aging

Abliva Ab

Isomerase Therapeutics, Ltd.

Wyeth

Biotica Technology Limited

Matthew Alan Gregory

Steven James Moss

Barrie Wilkinson

Sabine Gaisser

Hrvoje Petkovic

Christine Janet Martin

Magnus Joakim Hansson

Alvar Grönberg

Steven Gary Kendrew

Mats Eskil Elmér

Mark Richard Farmery

Lee Robert Webster

Aleksandra Maria Wlodek

Richard Reumerman

Divyang Jani

The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.

Succinate prodrug, compositions containing the succinate prodrug and uses thereof

The present invention provides inter alia methods for generating a library of cells producing polyketides and selecting for these strains based on binding to a protein target.

Methods for producing hybrid polyketide synthase genes and polyketides

The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.

The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.

Use of sanglifehrin macrocyclic analogues as anticancer compounds

A method for increasing the molecular diversity of polyketides and non-ribosomal peptides by using recombination to efficiently increase or decrease the number of modules in the polyketide synthase or non-ribosomal peptide synthetase encoding the polyketide or peptide.

Methods for increasing molecular diversity of polyketides and non-ribosomal proteins

The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).

Production of polyketides and other natural products

There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

Dosage form

Novel rapamycin analogues and methods for their production with FKBP and/or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.

Rapamycin analogues and their pharmaceutical use

There is provided inter alia a compound of formula (I) or a pharmaceutically acceptable salt thereof and its use in therapy. 

Rapamycin analogue

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.

Sanglifehrin derivatives and methods for their production

There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.

Macrocyclic compounds and methods for their production

There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.

Sanglifehrin based compounds

There is provided inter alia a compound of formula (I): for use in treatment of viral infection or as an immunosuppressant.

Compound and methods for its production

The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogs and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogs and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogs, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).

The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in aspect the present invention provides 17-desmethylrapamycin and analogues thereof, methods for their production, including recombinant strains, and isolation and uses of the compounds of the invention. In a further aspect the present invention provides for the use of 17-desmethylrapamycin and analogues thereof in the induction or maintenance of immunosuppression, the stimulation of neuronal regeneration or the treatment of cancer, B-cell malignancies, fungal infections, transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation vascular disease and fibrotic diseases, and in the regulation of wound healing.

Growing community of inventors

Cambridge, United Kingdom

Matthew Alan Gregory